Related Experiment Video
Updated: May 18, 2026
05:49
Modeling the Effects of Hemodynamic Stress on Circulating Tumor Cells using a Syringe and Needle
Published on: April 27, 2021
Do circulating tumor cells play a role in coagulation and thrombosis?
Garth W Tormoen1, Kristina M Haley, Ross L Levine
1Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University Portland, OR, USA.
Frontiers in Oncology
|September 14, 2012
Summary
Cancer patients often experience blood clots, impacting prognosis. Early detection of cancer-associated thrombosis risk using circulating tumor cells (CTCs) could personalize anticoagulant prophylaxis and improve outcomes.
Area of Science:
- Oncology
- Hematology
- Biomedical Science
Background:
- Cancer patients have an increased risk of thrombosis, leading to poorer prognoses.
- Current anticoagulant prophylaxis is not routinely used due to complex patient and diagnosis factors.
- Early identification of at-risk patients is crucial for personalized treatment and reduced mortality.
Purpose of the Study:
- To review the evidence linking circulating tumor cells (CTCs) to cancer-associated hypercoagulability.
- To explore the potential of CTC detection platforms in assessing thrombosis risk.
- To highlight how CTC analysis can guide anticoagulant prophylaxis decisions.
Main Methods:
- Review of existing literature on cancer, thrombosis, and circulating tumor cells.
- Discussion of the role of CTCs in the pathogenesis of cancer-related hypercoagulability.
- Exploration of CTC detection technologies as prognostic tools.
Main Results:
- CTCs may play a significant role in the hypercoagulable state associated with cancer.
- Difficulty in identifying rare CTCs has limited previous research.
- Emerging CTC detection platforms offer new avenues for study.
Conclusions:
- Circulating tumor cells represent a potential biomarker for cancer-associated thrombosis risk.
- CTC detection platforms may enable personalized anticoagulant prophylaxis strategies.
- Further research into CTCs and coagulation is warranted to improve patient outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...